A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis
Latest Information Update: 18 Apr 2025
At a glance
- Drugs QUC 398 (Primary)
- Indications Musculoskeletal pain; Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 15 Apr 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Sponsor Decision.
- 08 Aug 2024 Planned End Date changed from 6 Oct 2025 to 4 Jul 2025.
- 12 Jun 2024 Status changed from recruiting to active, no longer recruiting.